HUE038234T2 - Bendamusztin és ciklopoliszacharid kompozíciók - Google Patents
Bendamusztin és ciklopoliszacharid kompozíciókInfo
- Publication number
- HUE038234T2 HUE038234T2 HUE14177306A HUE14177306A HUE038234T2 HU E038234 T2 HUE038234 T2 HU E038234T2 HU E14177306 A HUE14177306 A HU E14177306A HU E14177306 A HUE14177306 A HU E14177306A HU E038234 T2 HUE038234 T2 HU E038234T2
- Authority
- HU
- Hungary
- Prior art keywords
- bendamustine
- cyclopolysaccharide
- compositions
- cyclopolysaccharide compositions
- bendamustine cyclopolysaccharide
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/40—Cyclodextrins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US20854109P | 2009-02-25 | 2009-02-25 | |
US26994409P | 2009-07-01 | 2009-07-01 | |
US27136409P | 2009-07-20 | 2009-07-20 | |
US27929309P | 2009-10-19 | 2009-10-19 |
Publications (1)
Publication Number | Publication Date |
---|---|
HUE038234T2 true HUE038234T2 (hu) | 2018-10-29 |
Family
ID=42631521
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HUE14177306A HUE038234T2 (hu) | 2009-02-25 | 2010-02-24 | Bendamusztin és ciklopoliszacharid kompozíciók |
Country Status (12)
Country | Link |
---|---|
US (2) | US8436032B2 (hu) |
EP (2) | EP2400987B1 (hu) |
JP (1) | JP5654498B2 (hu) |
KR (1) | KR101798951B1 (hu) |
CN (2) | CN102421451B (hu) |
AU (1) | AU2010217297A1 (hu) |
CA (1) | CA2753641C (hu) |
ES (2) | ES2525257T3 (hu) |
HU (1) | HUE038234T2 (hu) |
NO (1) | NO2792369T3 (hu) |
RU (2) | RU2591804C2 (hu) |
WO (1) | WO2010097700A1 (hu) |
Families Citing this family (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2525257T3 (es) | 2009-02-25 | 2014-12-19 | Supratek Pharma, Inc. | Composiciones de ciclopolisacárido y de bendamustina |
LT2528602T (lt) | 2010-01-28 | 2017-02-27 | Eagle Pharmaceuticals, Inc. | Bendamustino kompozicijos |
WO2011103150A2 (en) * | 2010-02-18 | 2011-08-25 | Cephalon, Inc. | Lyophilized preparations of bendamustine |
US20110207764A1 (en) * | 2010-02-23 | 2011-08-25 | Valery Alakhov | Cyclopolysaccharide compositions |
US8383663B2 (en) | 2010-07-19 | 2013-02-26 | Supratek Pharma Inc. | Bendamustine anionic-catioinic cyclopolysaccharide compositions |
WO2013040286A2 (en) * | 2011-09-18 | 2013-03-21 | Euro-Celtique S.A. | Pharmaceutical compositions |
TWI573792B (zh) | 2012-02-01 | 2017-03-11 | 歐陸斯迪公司 | 新穎治療劑 |
PT3533447T (pt) | 2012-03-20 | 2023-05-17 | Eagle Pharmaceuticals Inc | Composições líquidas de bendamustina para utilização num método de tratamento de condições com resposta a bendamustina em pacientes que requerem volumes reduzidos para administração |
EP2827862B1 (en) | 2012-03-20 | 2023-12-27 | Eagle Pharmaceuticals, Inc. | Formulations of bendamustine |
US20230241218A1 (en) * | 2012-07-10 | 2023-08-03 | Eagle Pharmaceuticals, Inc. | Formulations of bendamustine |
AU2013352141B2 (en) * | 2012-11-30 | 2018-04-05 | The Regents Of The University Of California | Anticonvulsant activity of steroids |
EP3043648B1 (en) * | 2013-08-27 | 2023-09-20 | Vasilios VOUDOURIS | Bendamustine pharmaceutical compositions |
GB201409488D0 (en) | 2014-05-28 | 2014-07-09 | Euro Celtique Sa | Pharmaceutical composition |
GB201409471D0 (en) | 2014-05-28 | 2014-07-09 | Euro Celtique Sa | Pharmaceutical composition |
GB201409485D0 (en) | 2014-05-28 | 2014-07-09 | Euro Celtique Sa | Pharmaceutical composition |
WO2018068832A1 (en) | 2016-10-11 | 2018-04-19 | Euro-Celtique S.A. | Hodgkin lymphoma therapy |
GB201709405D0 (en) | 2017-06-13 | 2017-07-26 | Euro Celtique Sa | Compounds for treating ovarian cancer |
GB201709402D0 (en) | 2017-06-13 | 2017-07-26 | Euro Celtique Sa | Compounds for treating t-pll |
GB201709403D0 (en) | 2017-06-13 | 2017-07-26 | Euro Celtique Sa | Compounds for treating sarcoma |
GB201709406D0 (en) | 2017-06-13 | 2017-07-26 | Euro-Cletique S A | Compounds for treating TNBC |
CN111201019A (zh) * | 2017-10-05 | 2020-05-26 | 图贝药物有限公司 | 口服苯达莫司汀制剂 |
US11730815B2 (en) * | 2018-11-26 | 2023-08-22 | Good Health, Llc | Stable liquid pharmaceutical compositions comprising bendamustine |
CN111557904A (zh) * | 2020-04-09 | 2020-08-21 | 比卡生物科技(广州)有限公司 | 苯达莫司汀组合物及其用途 |
JP2023529033A (ja) * | 2020-04-09 | 2023-07-07 | ビカ・バイオテック(グアンジョウ)・カンパニー・リミテッド | ベンダムスチン組成物及びその用途 |
US20240148696A1 (en) | 2022-10-25 | 2024-05-09 | Softkemo Pharma Inc. | Lyophilized bendamustine-cyclodextrin composition |
Family Cites Families (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DD159289A1 (de) | 1981-06-01 | 1983-03-02 | Uwe Olthoff | Verfahren zur herstellung stabiler injektionsloesungen von n-lostverbindungen |
US6407079B1 (en) | 1985-07-03 | 2002-06-18 | Janssen Pharmaceutica N.V. | Pharmaceutical compositions containing drugs which are instable or sparingly soluble in water and methods for their preparation |
US5068226A (en) * | 1987-12-07 | 1991-11-26 | Cyclex, Inc. | Pharmaceutical preparations containing cyclodextrins and their use in iontophoretic therapies |
US5602112A (en) | 1992-06-19 | 1997-02-11 | Supergen, Inc. | Pharmaceutical formulation |
DE59607089D1 (de) * | 1995-03-10 | 2001-07-19 | Roche Diagnostics Gmbh | Polypeptid-enthaltende pharmazeutische darreichungsformen in form von mikropartikeln und verfahren zu deren herstellung |
DK0814778T3 (da) * | 1995-03-10 | 2001-09-17 | Roche Diagnostics Gmbh | Polypeptidholdige farmaceutiske administrationsformer i form af mikropartikler og fremgangsmåde til fremstilling deraf |
US6624141B1 (en) | 1999-03-17 | 2003-09-23 | The Regents Of The University Of Michigan | Protamine fragment compositions and methods of use |
DE10204792A1 (de) * | 2002-02-06 | 2003-08-14 | Merck Patent Gmbh | Lyophilisierte Zubereitung enthaltend Immuncytokine |
EP1499361B1 (en) | 2002-04-19 | 2012-08-08 | Novartis AG | Novel biomaterials, their preparation and use |
SG176314A1 (en) * | 2002-12-31 | 2011-12-29 | Altus Pharmaceuticals Inc | Human growth hormone crystals and methods for preparing them |
EP1729724A4 (en) * | 2003-12-31 | 2008-07-23 | Cydex Inc | INHALATION FORMULATION WITH SULFOALKYL ETHER GAMMA CYCLODEXTRIN AND CORTICOSTEROID |
JP2007530654A (ja) * | 2004-03-30 | 2007-11-01 | ファイザー・プロダクツ・インク | シグナル伝達阻害剤の組合せ |
CN1984674A (zh) * | 2004-06-07 | 2007-06-20 | 纳斯泰克制药公司 | 不含蛋白质或多肽类稳定剂的干扰素β鼻内制剂 |
NZ553024A (en) * | 2004-08-03 | 2009-11-27 | Royal College Of Surgeons Ie | Phenytoin formulations, and uses thereof in wound healing |
JP2008519032A (ja) * | 2004-11-03 | 2008-06-05 | キュラジェン コーポレイション | Fgf−20の調合物、生成方法および使用 |
US20060128777A1 (en) * | 2004-11-05 | 2006-06-15 | Bendall Heather H | Cancer treatments |
US20060128653A1 (en) * | 2004-12-10 | 2006-06-15 | Chunlin Tang | Pharmaceutical formulation of decitabine |
UA94036C2 (ru) * | 2005-01-14 | 2011-04-11 | Сефалон, Инк. | Фармацевтическая композиция бендамустина, предназначенная для лиофилизации |
US8436190B2 (en) | 2005-01-14 | 2013-05-07 | Cephalon, Inc. | Bendamustine pharmaceutical compositions |
PT1848813E (pt) | 2005-01-28 | 2013-07-15 | Scripps Research Inst | Activação de glicolípidos bacterianos de células nkt restritas ao cd1d |
US8158152B2 (en) * | 2005-11-18 | 2012-04-17 | Scidose Llc | Lyophilization process and products obtained thereby |
CN1846685A (zh) | 2006-01-25 | 2006-10-18 | 济南帅华医药科技有限公司 | 含苯达莫司汀和其增效剂的缓释注射剂 |
US20100143481A1 (en) | 2006-11-08 | 2010-06-10 | Dinesh Shenoy | Method of preparing solid dosage forms of multi-phasic pharmaceutical compositions |
US8425459B2 (en) * | 2006-11-20 | 2013-04-23 | Lutonix, Inc. | Medical device rapid drug releasing coatings comprising a therapeutic agent and a contrast agent |
ES2373867T3 (es) | 2007-03-02 | 2012-02-09 | The University Of Wollongong | Composiciones y procedimientos para el suministro de agentes anticancerosos. |
CN101219113A (zh) | 2008-01-28 | 2008-07-16 | 济南帅华医药科技有限公司 | 含苯达莫司汀的复方抗癌缓释注射剂 |
ES2525257T3 (es) | 2009-02-25 | 2014-12-19 | Supratek Pharma, Inc. | Composiciones de ciclopolisacárido y de bendamustina |
CN101606934B (zh) | 2009-07-27 | 2011-09-28 | 江苏奥赛康药业有限公司 | 盐酸苯达莫司汀组合物 |
-
2010
- 2010-02-24 ES ES10745872.1T patent/ES2525257T3/es active Active
- 2010-02-24 EP EP10745872.1A patent/EP2400987B1/en active Active
- 2010-02-24 JP JP2011550669A patent/JP5654498B2/ja active Active
- 2010-02-24 RU RU2011138844/15A patent/RU2591804C2/ru not_active Application Discontinuation
- 2010-02-24 WO PCT/IB2010/000502 patent/WO2010097700A1/en active Application Filing
- 2010-02-24 CN CN2010800183017A patent/CN102421451B/zh active Active
- 2010-02-24 NO NO14177306A patent/NO2792369T3/no unknown
- 2010-02-24 AU AU2010217297A patent/AU2010217297A1/en not_active Abandoned
- 2010-02-24 CN CN2012104076231A patent/CN102935080A/zh active Pending
- 2010-02-24 RU RU2016124871A patent/RU2734236C2/ru not_active Application Discontinuation
- 2010-02-24 US US12/711,979 patent/US8436032B2/en active Active
- 2010-02-24 ES ES14177306.9T patent/ES2675620T3/es active Active
- 2010-02-24 EP EP14177306.9A patent/EP2792369B1/en active Active
- 2010-02-24 KR KR1020117022330A patent/KR101798951B1/ko active IP Right Grant
- 2010-02-24 CA CA2753641A patent/CA2753641C/en active Active
- 2010-02-24 HU HUE14177306A patent/HUE038234T2/hu unknown
-
2013
- 2013-03-11 US US13/793,442 patent/US8703964B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
KR20120015294A (ko) | 2012-02-21 |
CA2753641A1 (en) | 2010-09-02 |
RU2734236C2 (ru) | 2020-10-13 |
WO2010097700A1 (en) | 2010-09-02 |
AU2010217297A1 (en) | 2011-10-20 |
US8436032B2 (en) | 2013-05-07 |
JP5654498B2 (ja) | 2015-01-14 |
NO2792369T3 (hu) | 2018-09-15 |
ES2525257T3 (es) | 2014-12-19 |
EP2792369B1 (en) | 2018-04-18 |
RU2011138844A (ru) | 2013-04-10 |
CA2753641C (en) | 2014-09-16 |
CN102421451A (zh) | 2012-04-18 |
KR101798951B1 (ko) | 2017-11-20 |
RU2016124871A3 (hu) | 2019-11-11 |
ES2675620T3 (es) | 2018-07-11 |
CN102935080A (zh) | 2013-02-20 |
EP2400987A4 (en) | 2012-08-22 |
EP2400987A1 (en) | 2012-01-04 |
US8703964B2 (en) | 2014-04-22 |
CN102421451B (zh) | 2013-11-06 |
US20100216858A1 (en) | 2010-08-26 |
RU2016124871A (ru) | 2018-12-04 |
JP2012519657A (ja) | 2012-08-30 |
US20130190372A1 (en) | 2013-07-25 |
EP2400987B1 (en) | 2014-09-03 |
EP2792369A1 (en) | 2014-10-22 |
RU2591804C2 (ru) | 2016-07-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HUE038234T2 (hu) | Bendamusztin és ciklopoliszacharid kompozíciók | |
IL217949A0 (en) | Pesticdal compositions | |
EP2488022A4 (en) | Compositions | |
ZA201109176B (en) | Homeglobin compositions | |
GB0906515D0 (en) | Fungical compositions | |
GB0908129D0 (en) | Composition | |
GB0918450D0 (en) | Composition | |
ZA201109312B (en) | Compositions | |
GB0909362D0 (en) | Composition | |
PL2226355T3 (pl) | Kompozycje poliolefinowe sieciowane wilgocią | |
GB0908642D0 (en) | Composition | |
GB0901966D0 (en) | Composition | |
EP2394634A4 (en) | HESPERIDO-CONTAINING COMPOSITION | |
GB0906779D0 (en) | Composition | |
EP2595660A4 (en) | ANIONIC-CATIONIC BENDAMUSTIN CYCLOPOLYSACCHARIDE COMPOSITIONS | |
GB0911294D0 (en) | Composition | |
GB0904941D0 (en) | Composition | |
EP2485807A4 (en) | SUN PROTECTION COMPOSITIONS | |
EP2444061A4 (en) | COMPOSITION CONTAINING APIGENIN | |
GB0905165D0 (en) | Compositions | |
GB0906548D0 (en) | Composition | |
GB0904942D0 (en) | Composition | |
GB0918590D0 (en) | Composition | |
GB0903688D0 (en) | Composition | |
GB0902959D0 (en) | Composition |